FIA
CTMX icon

FNY Investment Advisers’s CytomX Therapeutics CTMX Stock Holding History

FNY Investment Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,500
Closed -$6K – 560
2023
Q1 		$6K Sell
4,500
-60,500
-93% -$137K 0.01% 377
2022
Q4 		$104K Buy
+65,000
New +$96.2K 0.15% 133

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FNY Investment Advisers's CTMX Position: Q2 2023 in Review

FNY Investment Advisers sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 4,500 shares — an estimated $6K sold.

FNY Investment Advisers first reported a position in CTMX in Q4 2022 and held it in 2 quarters. The position peaked at $104K in Q4 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

  • FNY Investment Advisers reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 4,500 CytomX Therapeutics shares in Q2 2023, an estimated $6K.
  • FNY Investment Advisers first reported a position in CytomX Therapeutics in Q4 2022 and held it in 2 quarters.
  • FNY Investment Advisers's CytomX Therapeutics position peaked at $104K in Q4 2022.
  • 67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on FNY Investment Advisers's 13F filing for Q2 2023, filed 11 Jul 2023.